Stock Blog Hub » MYGN

(QGEN) Qiagen Expands with New Deals

vitalstocks — Fri, 13 Jan 2012 21:09:44 +0000

In an attempt to expand its companion diagnostic portfolio for several types of new anti-cancer drugs, Qiagen (QGEN) recently entered into two different agreements with US biotech companies, namely Insight Genetics, Inc. and Personal Genome Diagnostics Inc. Through the agreement, the company seeks to obtain worldwide exclusive rights for biomarkers for gene mutation. In collaboration [...]

(QGEN) Qiagen Expands with New Deals

(MYGN) Myriad Genetics Analyst Uprades Shares to Outperform

vitalstocks — Fri, 01 Jul 2011 16:39:43 +0000

Recently, we upgraded Myriad Genetics (MYGN) to Outperform with a target price of $27.00. Myriad is confident of retaining the momentum recorded over the past few quarters going ahead through product portfolio expansion, targeting the companion diagnostic market and expansion into Europe. With respect to new products, Myriad aims to launch at least one new [...]

(MYGN) Myriad Genetics Analyst Uprades Shares to Outperform

(MYGN) Myriad Genetics – Bull of the Day

vitalstocks — Fri, 01 Jul 2011 16:39:03 +0000

Myriad Genetics’ (MYGN) flagship product, Bracanalysis, has been recording robust growth over the past few quarters. Moreover, the company is undertaking strategies to expand the scope of the test. A strong cash balance enables the company to buyback shares, expand into new markets and introduce more products. Moreover, the acquisition of RMB will help diversify [...]

(MYGN) Myriad Genetics – Bull of the Day

(ANGO) Company News for June 16, 2011 – Corporate Summary

vitalstocks — Thu, 16 Jun 2011 15:20:38 +0000

• Share prices of Scotts Miracle-Gro Company (NYSE:SMG) dipped 6.02% after the company reduced its earnings estimate for the fiscal year 2011 • Shares of Owens-Illinois (NYSE:OI) dropped 13.54% to close at $25.54 after the company said its second quarter earnings figures could fall due to a jump in manufacturing and delivery expenses • Johnson [...]

(ANGO) Company News for June 16, 2011 – Corporate Summary

(MYGN) Myriad Genetics and BioMarin Pharmaceuticals Enter Agreement for Testing

vitalstocks — Sat, 09 Apr 2011 19:13:47 +0000

Myriad Genetics (MYGN) has entered into an agreement with BioMarin Pharmaceuticals (BMRN) to conduct BRCA1 and BRCA2 mutation testing on patients to be enrolled in the latter’s phase I/II clinical study of BMN 673. BMN 673 is a PARP-inhibitor drug candidate for treatment of genetically defined cancers. Bracanalysisis Myriad’s flagship product, contributing 89% of total [...]

(MYGN) Myriad Genetics and BioMarin Pharmaceuticals Enter Agreement for Testing

(HUM) June 2010 – Industry Outlook – Health Care Stock Review

vitalstocks — Thu, 03 Jun 2010 13:12:27 +0000

The health care sector comprises different industries, ranging from managed care organizations, healthcare facilities providers and medical devices manufacturers to biotech and pharmaceutical companies. Consequently, we believe that investors in this sector should be mindful of the different drivers and appropriate metrics associated with the various sub-sectors. In March 2010, U.S. healthcare reform passed through [...]

(HUM) June 2010 – Industry Outlook – Health Care Stock Review

(MYGN) Myriad Genetics – Bear of the Day

vitalstocks — Mon, 24 May 2010 04:26:33 +0000

Myriad Genetics Inc.’s (MYGN) third quarter fiscal 2010 earnings of $0.33 per share fell short of the Zacks Consensus Estimate by $0.05. The company had earned $0.38 per share in the year-ago period. Myriad Genetics spun off its therapeutics business in July 2009 to focus on molecular diagnostics going forward. Although the molecular diagnostics business [...]

(MYGN) Myriad Genetics – Bear of the Day

(MYGN) Myriad Surpasses Consensus Estimates

vitalstocks — Thu, 04 Feb 2010 22:59:07 +0000

Myriad Genetics Inc. (MYGN) reported second quarter fiscal 2010 earnings of 36 cents per share, two cents above the Zacks Consensus Estimate. The company had earned 22 cents in the year-ago period. The year-ago earnings were inclusive of a loss of $15.6 million from discontinued operations pertaining to Myriad’s former research and pharmaceutical businesses. Detailed [...]

(MYGN) Myriad Surpasses Consensus Estimates

(MYGN) Myriad Genetics Upgraded to Neutral

vitalstocks — Thu, 17 Dec 2009 18:42:24 +0000

We have upgraded Myriad Genetics (MYGN) to Neutral from Underperform based on the impressive performance of its molecular diagnostics business. Effective July 1, 2009, the company spun off its therapeutics business to focus on molecular diagnostics. We believe that the de-risking strategy to separate the profitable predictive medicine business from the higher risk drug development [...]

(MYGN) Myriad Genetics Upgraded to Neutral

(MYGN) Myriad Genetics – Bear of the Day

vitalstocks — Mon, 16 Nov 2009 18:22:04 +0000

Myriad Genetics Inc. (MYGN) reported first quarter fiscal 2010 earnings of 31 cents per share, which was below the Zacks Consensus Estimate by a penny. The company had earned 25 cents per share in the year-ago period. Myriad Genetics spun off its therapeutics business in July 2009 to focus on molecular diagnostics going forward. Although [...]

(MYGN) Myriad Genetics – Bear of the Day

(MYGN) Myriad Genetics Inc Misses Forecasts by a Penny

vitalstocks — Mon, 09 Nov 2009 03:23:45 +0000

Myriad Genetics Inc. (MYGN) reported fiscal first-quarter earnings of 31 cents per share, a penny behind the Zacks Consensus Estimate. The company had earned 25 cents in the year-ago period. Molecular diagnostic revenues for the quarter came in at $85.12 million as against $69.97 million in the prior-year quarter, a 21.6% increase. The improvement was [...]

(MYGN) Myriad Genetics Inc Misses Forecasts by a Penny

(MYGN) Myriad Reports Strong Earnings of 37 Cents vs. 23 Cents Estimate

vitalstocks — Wed, 26 Aug 2009 16:09:50 +0000

Yesterday, Myriad Genetics Inc. (MYGN) reported fourth quarter earnings of 37 cents per share from continuing operations. This was well above the Zacks Consensus Estimate of 23 cents. For fiscal year 2009, the company earned $1.38 per share from continuing operations. Molecular Diagnostic Revenues for the quarter came in at $86.1 million, versus $64.7 million [...]

(MYGN) Myriad Reports Strong Earnings of 37 Cents vs. 23 Cents Estimate

(MYGN) Biotech Industry – Zacks Analyst Interviews

vitalstocks — Mon, 01 Jun 2009 23:05:04 +0000

OVERVIEW The Biotech industry as a whole continues to underperform the market so far this year. As of May 26, 2009, Both the AMEX Biotech Index and the broader NASDAQ Biotech Index declined 6.8% (AMEX Biotech has 20 biotech companies while NASDAQ Biotech Index includes over 130 component companies), while the Dow Jones Biotech Index [...]

(MYGN) Biotech Industry – Zacks Analyst Interviews

(MYGN) Myriad Genetics, Inc. – Momentum – Zacks Rank Buy

vitalstocks — Mon, 16 Mar 2009 22:46:46 +0000

Myriad Genetics, Inc. (MYGN) continues to head higher after the company reported strong earnings on Feb 3 and announced a 2-for-1 stock split on Feb 24. Second-Quarter Results Much of Myriad’s recent price strength is built upon the company’s solid second-quarter results. Revenue was up an impressive 49% from last year to $84.4 million. Profit [...]

(MYGN) Myriad Genetics, Inc. – Momentum – Zacks Rank Buy

(MYGN) Myriad Genetics – Revenues increased 58%, on a year-over-year basis

vitalstocks — Tue, 10 Feb 2009 19:54:30 +0000

Myriad Genetics, Inc. (MYGN) has just reported a fantastic quarter and shares have responded. Analysts are responding with sharp increases in earnings estimates. Company Description Myriad Genetics uses gene-based medicine to develop therapeutic and molecular diagnostic products. The company employs a variety of proprietary proteomic technologies to discover disease genes and to understand the role [...]

(MYGN) Myriad Genetics – Revenues increased 58%, on a year-over-year basis

(MYGN) Myriad Genetics – Revenue increased 53% from last year

Shawn — Thu, 15 Jan 2009 01:33:44 +0000

Myriad Genetics, Inc.’s (MYGN) share price continues to advance after the company reported a great quarter in early November. Analysts are bullish on the company, with the next-year estimate projecting 60% earnings growth. Company Description Myriad Genetics is a healthcare company that develops molecular diagnostic and therapeutic products. Its products include items to asses a [...]

(MYGN) Myriad Genetics – Revenue increased 53% from last year